On July 30, 2021 Avidin, as part of a special German-Hungarian collaborative program reported that it has successfully developed a reagent prototype product based on new, specific and high-sensitivity biochemical tests in the frame of a grant (2018-2.1.3-EUREKA-2018-00016) (Press release, Avidin, JUL 30, 2021, View Source [SID1234585572]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Biomarkers of oxidative stress play an important role in understanding pathogenesis and in treatment of these diseases. In the frame of the EUREKA grant the Hungarian partner of the consortium, in close cooperation with the two German partners, identified new molecular targets that can lead to cell death and pathological changes that originate from the mitochondria. Avidin has successfully developed a reagent prototype product based on new, specific and high-sensitivity biochemical tests. Biochemical kits will be combined with a cellular sensor developed in SIZ and with the genomic platform developed in GenXPro; complementing each other will produce a competitive product line. Initial co-operation will open up further collaborative opportunities in the long term and will allow the development of the products created here for diagnostic purposes.